134308-13-7

Basic information

• Product Name: Tolcapone
• Synonyms: 3,4-DIHYDROXYL-5-NITROBENZYL,4'-METHYLBENZENYL KETONE;TALCAPONE;TOLCAPONE;(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-methanon;(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone;3,4-dihydroxy-4’-methyl-5-nitrobenzophenone;ro40-7592;TolcaponeTolcapone
• CAS NO: 134308-13-7
• Molecular Formula: C₁₄H₁₁NO₅
• Molecular Weight: 273.24
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics;API;Inhibitor;Inhibitors
• Mol File: 134308-13-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 126-1280C
• Boiling Point: 485.6 °C at 760 mmHg
• Flash Point: 205.8 °C
• Appearance: yellow/
• Density: 1.419 g/cm³
• Vapor Pressure: 4.72E-10mmHg at 25°C
• Refractive Index: 1.661
• Storage Temp.: -20°C Freezer
• Solubility: DMSO: ≥15mg/mL
• PKA: 4.78±0.38(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.
• CAS DataBase Reference: Tolcapone(CAS DataBase Reference)
• NIST Chemistry Reference: Tolcapone(134308-13-7)
• EPA Substance Registry System: Tolcapone(134308-13-7)

Safety Data

• Hazard Codes: N
• Statements: 50
• Safety Statements: 61
• RIDADR: UN 3077 9 / PGIII
• RTECS: PC4952500
• Hazardous Substances Data: 134308-13-7(Hazardous Substances Data)

Usage

Description

Tolcapone (134308-13-7) is a catechol O-methyltransferase inhibitor (COMT), inhibiting both brain and peripheral enzymes.1?Potent inhibitor of alpha-synuclein and beta-amyloid oligomerization and fibrillogenesis protecting against extracellular toxicity.2?Binds to transthyretin (TTR) with high affinity (21 to 58 nM) and inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity?in vitro. Stabilizes TTR in mice and humans?in vivo.3?Inhibits O-methylation of exogenous polyphenols such as EGCG.4?Cell permeable. Orally bioavailable.

Chemical Properties

Yellow Solid

Originator

Tasmar,Roche

Uses

Different sources of media describe the Uses of 134308-13-7 differently. You can refer to the following data:
1. Orally active inhibitor of central and peripheral catechol-O-methyltransferase (COMT). Antiparkinsonian
2. Tolcapone may be used in COMT-mediated cell signaling studies.Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Preparation

preparation by demethylation of 4-hydroxy-3-methoxy-4′-methyl-5-nitrobenzophenone with hydrobromic acid in refluxing aque-ous acetic acid.

Manufacturing Process

Condensation of 4-benzyloxy-3-methoxybenzaldehyde with 4-lithium-toluene (prepared from 4-bromotoluene and butyl lithium) leads to the corresponding benzhydrole. Oxidation of the new formed hydroxyl in benzhydrole gives the 4-benzyloxy-3-methoxyphenyl)-p-tolylmethanone. Treatment of this compound with hydrogen bromide selectively removes the benzyl ether that is additionally activated by the transannular carbonyl group. The intermediate is then nitrated under standart conditions to give the (4-hydroxy-3-methoxy-5- nitrophenyl)-p-tolylmethanone. A second treatment of the last compound with hydrogen bromide cleaves the ether group, which is now activated by the adjacent nitro group. This last step affords the (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone.

Therapeutic Function

Antiparkinsonian

General Description

Tolcapone, 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone (Tasmar), is a yellow, odorless, nonhygroscopic,crystalline compound (pKa＝4.78). Tolcapone israpidly absorbed after oral administration. Tolcapone ishighly bound to plasma albumin (＞98%), and its distributionis therefore restricted. Tolcapone has low first-pass metabolism.It is almost completely metabolized in the liver before excretion, and 60% is excreted by the kidney. The majormetabolite of tolcapone is an inactive glucuronide conjugate.COMT inhibitors increase chronotropic and arrhythmogeniceffects of epinephrine.Tolcapone is indicated as an adjunctto levodopa/carbidopa for the management of signs andsymptoms of PD.

Biochem/physiol Actions

Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Clinical Use

Catechol-o-methyltransferase inhibitor: Treatment of Parkinson’s disease

Drug interactions

Potentially hazardous interactions with other drugs Antidepressants: avoid with MAOIs.

Metabolism

Extensively metabolised, mainly by conjugation to the inactive glucuronide, but methylation by catecholO-methyltransferase to 3-O-methyltolcapone and metabolism by cytochrome P450 isoenzymes CYP3A4 and CYP2A6 also occurs. Approximately 60% of a dose is excreted in the urine with the remainder appearing in the faeces.

References

1) Manisto?et al.?(1992),?Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat; Br, J. Pharmacol.,?105?569 2) Giovanni?et al.?(2010),?Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity;?J. Biol. Chem.,?285?14941 3) Sant’Anna?et al.?(2016),?Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity; Nat. Commun.,?7?10787 4) Forester and Lambert (2015),?The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice; Funct. Foods,?17?183

InChI:InChI=1/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

Upstream product

• 134612-80-9 3-O-Methyltolcapone 
• 1391053-03-4 C₁₄H₁₂O₃ 

Related news

Right inferior frontal cortex activity correlates with Tolcapone (cas 134308-13-7) responsivity in problem and pathological gamblers07/26/2019

Failures of self-regulation in problem and pathological gambling (PPG) are thought to emerge from failures of top-down control, reflected neurophysiologically in a reduced capacity of prefrontal cortex to influence activity within subcortical structures. In patients with addictions, these impair...detailed

Comparison of the inhibitory effects of Tolcapone (cas 134308-13-7) and entacapone against human UDP-glucuronosyltransferases07/25/2019

Tolcapone and entacapone are two potent catechol-O-methyltransferase (COMT) inhibitors with a similar skeleton and displaying similar pharmacological activities. However, entacapone is a very safe drug used widely in the treatment of Parkinson's disease, while tolcapone is only in limited u...detailed

Relevant articles and documents

Convenient synthesis of tolcapone, a selective catechol-O-methyltransferase inhibitor

A convenient and efficient synthesis of tolcapone from commercial 4-benzyloxy-3-methoxybenzaldehyde is presented. Grignard reaction of 4-benzyloxy-3-methoxybenzaldehyde (1) with p-tolylmagnesium bromide followed by Oppenauer oxidation of the hydroxyl func

Catechol derivatives

Catechol derivatives of the formula STR1 wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.